Role of plasminogen activator inhibitor-1 in coronary pathophysiology. Issue 164 (April 2018)

• Record Type: Journal Article
• Authors: Jung, Richard G.; Simard, Trevor; Labinaz, Alisha; Ramirez, F. Daniel; Di Santo, Pietro; Motazedian, Pouya; Rochman, Rebecca; Gaudet, Chantal; Faraz, Mohammad Ali; Beanlands, Rob S.B.; Hibbert, Benjamin
• Is Part Of: Thrombosis research. Issue 164(2018)
• Page Start: 54
• Page End: 62
• Publication Date: 2018-04
• Subjects: Plasminogen activator inhibitor-1 -- Coronary artery disease -- Percutaneous coronary intervention -- Biomarker -- Stent thrombosis -- In-stent restenosis; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2018.02.135
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: The standard of care for obstructive atherosclerotic coronary disease is revascularization, predominantly achieved via percutaneous placement of a stent with concurrent medical therapy. Advancements in percutaneous coronary intervention (PCI) have dramatically improved outcomes. However, major complications from PCI due to target lesion failure continue to occur at rates between 5 and 10% in the first twelve months following intervention limiting its therapeutic efficacy. Plasminogen activator inhibitor-1 (PAI-1) is a protein of interest for both arterial remodeling and thrombotic risk as it regulates cell migration and vascular thrombosis. Elevated PAI-1 antigen levels have been identified as a potential biomarker for coronary artery disease and metabolic syndrome while being modulated by a number of atherosclerotic risk factors. Although linked by some studies as a marker of disease severity and prognosis, it remains to be understood whether it is also a mediator and/or therapeutic target of vascular disease. In this review, we discuss the current understanding of PAI-1 in vascular disease and its potential role in in-stent restenosis and stent thrombosis. Highlights: Plasminogen activator inhibitor-1 (PAI-1) controls arterial remodeling & thrombosis. Elevated PAI-1 has been identified as a potential biomarker for vascular disease. PAI-1 has been implicated in in-stent restenosis and stent thrombosis. Therapeutics against PAI-1 has shown promising results in pre-clinical models.